Company
PhotoCure ASA
Headquarters: Oslo, Norway
Employees: 87
CEO: Mr. Daniel Schneider
Market Cap
kr1.58 Billion
NOK as of July 1, 2024
US$148.3 Million
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Detailed Description
Photocure ASA, a specialty pharmaceutical company, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the Netherlands, other European Countries, and the United States. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus infection and precancerous lesions of the cervix. The company sells its products to license partners, pharmaceutical wholesalers, pharmacies, and hospitals. Photocure ASA was founded in 1997 and is headquartered in Oslo, Norway.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Stocks & Indices
PhotoCure ASA has the following listings and related stock indices.
Stock: OSE: PHO wb_incandescent
Stock: OSE: PHOO wb_incandescent
Stock: FSX: PHS wb_incandescent
Stock: OTC: PHCUF wb_incandescent